• Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Articles
  • Clinical Trials
  • Specialists
  • Members
  • Media
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Observational Study
  • RareRevolution
  • New Members
  • More
    • Home
    • Welcome
    • CAD & Treatments
    • Donation
    • Resources
    • Webinar Resources
    • Register Web Series
    • Latest News & Articles
    • Clinical Trials
    • Specialists
    • Members
    • Media
    • Our Stories
    • Stay In The Know
    • Medical Advisors
    • Contact Us
    • Privacy & Policies
    • E-Learning Education
    • Observational Study
    • RareRevolution
    • New Members
  • Sign In
  • Create Account
  • My Account

  • Signed in as:

  • filler@godaddy.com

  • My Account

  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Articles
  • Clinical Trials
  • Specialists
  • Members
  • Media
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Observational Study
  • RareRevolution
  • New Members

Account

  • My Account

  • Sign out

  • Sign In
  • My Account

WELCOME TO THE COLD AGGLUTININ DISEASE FOUNDATION

Sanofi | Enjamo News

  Enjaymo™ News Releases

Press Release: European Commission approves Enjaymo® (pdf)

Download

CHMP recommends approval of Enjaymo™ (pdf)

Download

FDA approves and recommends Enjaymo™ (pdf)

Download

Introducing ENJAYMO– Treatment in Cold Agglutinin Disease (CAD). (pdf)

Download

Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Contact Us: info@cadfadvocacy.org

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept